Literature DB >> 7097501

Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans.

J A Clements, W S Nimmo, I S Grant.   

Abstract

The pharmacokinetics of ketamine in analgesic doses after intravenous, intramuscular, and oral administration was investigated in healthy volunteers. Plasma ketamine concentration-time curves were fitted by a two-compartment open model with a terminal half-life of 186 min. Absorption after intramuscular injection was rapid and the bioavailability was 93%. However, only 17% of an oral dose was absorbed because of extensive first-pass metabolism. Simultaneous measurements of the elevation of pain threshold in an ischemic exercise test showed a marked effect for 15-60 min after intramuscular injection, but little or no effect after the oral solution. Pain threshold elevation occurred at plasma ketamine concentrations above 160 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097501     DOI: 10.1002/jps.2600710516

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  58 in total

1.  Morphine, but not ketamine, decreases the ratio of Th1/Th2 in CD4-positive cells through T-bet and GATA3.

Authors:  Mei Gao; Jie Sun; Wenjie Jin; Yanning Qian
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.

Authors:  Samuel Fanta; Mari Kinnunen; Janne T Backman; Eija Kalso
Journal:  Eur J Clin Pharmacol       Date:  2015-03-01       Impact factor: 2.953

3.  S-ketamine concentrations are greatly increased by grapefruit juice.

Authors:  Marko A Peltoniemi; Teijo I Saari; Nora M Hagelberg; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

Review 4.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

Review 5.  Ketamine enantiomers in the rapid and sustained antidepressant effects.

Authors:  John Muller; Sahana Pentyala; James Dilger; Srinivas Pentyala
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

6.  Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

Authors:  Scott A Irwin; Alana Iglewicz; Richard A Nelesen; Jessica Y Lo; Connie H Carr; Sheilani D Romero; Linda S Lloyd
Journal:  J Palliat Med       Date:  2013-06-27       Impact factor: 2.947

7.  EFFICACY AND SAFETY OF ORAL KETAMINE PREMEDICATION IN CHILDREN UNDERGOING DAY CASE SURGERY.

Authors:  O O Oyedepo; A A Nasir; L O Abdur-Rahman; I K Kolawole; B O Bolaji; O A Ige
Journal:  J West Afr Coll Surg       Date:  2016 Jan-Mar

8.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.

Authors:  Jaclyn N Highland; Patrick J Morris; Panos Zanos; Jacqueline Lovett; Soumita Ghosh; Amy Q Wang; Carlos A Zarate; Craig J Thomas; Ruin Moaddel; Todd D Gould
Journal:  J Psychopharmacol       Date:  2018-11-29       Impact factor: 4.153

9.  Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Authors:  Manish K Jha; Madhukar H Trivedi
Journal:  Focus (Am Psychiatr Publ)       Date:  2018-07-18

10.  Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review.

Authors:  Paul Glue; Bruce Russell; Natalie J Medlicott
Journal:  Eur J Clin Pharmacol       Date:  2020-11-18       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.